Seropositivity to tumour antigens as a potential new biomarker for melanoma relapse - European Medical Journal

Seropositivity to tumour antigens as a potential new biomarker for melanoma relapse

Oncology
At the European Cancer Congress (ECC) 2015, Paul Nathan, MB.BS, BSc (Hons), BA, PhD, FRCP, of Mount Vernon Cancer Centre, Northwood, UK, discusses a study that was designed to determine whether seropositivity to a panel of tumour antigens was associated with a risk of relapse in patients with stage II and III melanoma.

Join our mailing list

To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now